Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Down 32.5% in May

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw a large drop in short interest during the month of May. As of May 31st, there was short interest totalling 19,700 shares, a drop of 32.5% from the May 15th total of 29,200 shares. Based on an average daily volume of 9,600 shares, the days-to-cover ratio is currently 2.1 days. Approximately 0.3% of the company’s shares are short sold.

Cumberland Pharmaceuticals Price Performance

Shares of NASDAQ CPIX traded down $0.04 during trading hours on Friday, hitting $1.51. 2,328 shares of the stock were exchanged, compared to its average volume of 7,370. The company’s fifty day simple moving average is $1.57 and its two-hundred day simple moving average is $1.79. Cumberland Pharmaceuticals has a 1-year low of $1.38 and a 1-year high of $2.36. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.21 and a current ratio of 1.37. The company has a market cap of $21.43 million, a PE ratio of -2.56 and a beta of 0.23.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter. The company had revenue of $8.50 million during the quarter. Cumberland Pharmaceuticals had a negative net margin of 21.67% and a positive return on equity of 0.21%.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Cumberland Pharmaceuticals in a research report on Tuesday, June 11th. They issued a “hold” rating for the company.

Institutional Trading of Cumberland Pharmaceuticals

A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp bought a new stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned 0.52% of Cumberland Pharmaceuticals at the end of the most recent reporting period. 15.51% of the stock is owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.